Organisation paid for research Program year 2025 Source: CMS Open Payments

Compass Oncology

Neither a doctor nor a teaching hospital

Research payments

$328,958

78 payments

Through program year 2025, Compass Oncology is reported as receiving $328,958 in research payments, across 78 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $150,229 4
2021 Research $7,006 26
2020 Research $7,836 4
2019 Research $163,888 44

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $173,404 14 payments
  2. Boehringer Ingelheim International GmbH $146,837 28 payments
  3. Pharmacyclics LLC, An AbbVie Company $7,006 26 payments
  4. Novartis Pharmaceuticals Corporation $1,500 1 payment
  5. Incyte Corporation $212 9 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and safety in colorectal cancer $146,837 28 payments
  2. A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) $123,479 1 payment
  3. A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer $12,944 6 payments
  4. A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) $11,950 1 payment
  5. A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer with Curative Intent Artemide Biliary01 $8,750 1 payment
  6. Study of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration Resistant Prostate Cancer PROfound Study $7,905 2 payments
  7. A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) $6,050 1 payment
  8. informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) $4,982 17 payments
  9. A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations PROfound $2,326 2 payments
  10. Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. $2,024 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record